WASHINGTON: Conflicting rulings by two federal judges have left the future of abortion pills in the United States deeply uncertain, likely placing the divisive issue squarely in the lap of the Supreme Court.
A ruling Friday by federal judge Matthew Kacsmaryk in Texas banned the widely used drug mifepristone (RU 486) nationwide, boosting conservatives’ efforts to further restrict abortion rights after the Supreme Court last year allowed states to prohibit them.
The unprecedented rejection of a drug approved in 2000 by the US Food and Drug Administration (FDA) — and found safe by scientific consensus — sparked outrage on the political left.
Kacsmaryk, in his ruling, adopted language used by abortion opponents, referring to abortion providers as “abortionists” and saying the drug was used to “kill the unborn human.” His ruling brought an immediate vow from the Biden administration and the drug’s maker to appeal the matter in federal court.
Attorney General Merrick Garland said the Justice Department would ask the appeals court to stay the ban by Kacsmaryk, an ultraconservative Donald Trump appointee, until the case is finally resolved.
If the Texas ruling holds, it would complicate matters not just in the states now banning or sharply limiting abortions, but also in those where the procedure remains legal.
Widely used
Mifepristone has been used as part of a two-drug regimen by 5.6 million women since 2000. But adding to the uncertainty and increasing the odds the matter ends up before the Supreme Court was a contradictory ruling from a Washington state judge that came just hours after Kacsmaryk’s.
District Judge Thomas Rice, a Barack Obama appointee, ruled in a separate case — brought by several states where abortion is legal — that mifepristone is “safe and legal” and that the FDA must preserve access to it in more than a dozen states.
For now the drug remains legal, Alexis McGill Johnson, the head of Planned Parenthood, one of the largest pro-abortion groups in the country, said.
Several abortion clinics also said that they would continue using mifepristone until ordered not to by the FDA, US media reported.
Kacsmaryk paused the effect of his ruling for a week, allowing time for the administration and drugmaker Danco Laboratories to file before the US Fifth Circuit Court of Appeals in Louisiana, which hears cases from Texas. The Justice Department is still reviewing Rice’s ruling, Garland said in a statement.
‘Remains safe’
Given the sharply conflicting court rulings, the Justice Department might opt to take the case directly to the Supreme Court and not wait for the Fifth Circuit to act.
The high court could decide to take up the case on an emergency basis, which would require making room in an already crowded agenda at the end of the current term.
In that case, the court — with six conservative justices outnumbering the three liberals — could hear the case within days, or weeks, but sometime before the current session ends on June 30.
Chief Justice John Roberts, a conservative, is deeply protective of the image of the institution, and he might be expected to vote with the three liberals in favor of mifepristone. The additional vote of one other conservative could provide a majority for the drug.
The court’s ruling last June to overturn the longstanding Roe v. Wade decision protecting abortion rights shifted considerable attention to medication abortions.
Published in Dawn, April 9th, 2023
